Literature DB >> 20155319

The impact of ulcerative colitis on patients' lives compared to other chronic diseases: a patient survey.

David T Rubin1, Marla C Dubinsky, Remo Panaccione, Corey A Siegel, David G Binion, Sunanda V Kane, Joseph Hopper.   

Abstract

PURPOSE: This study was designed to identify the impact chronic ulcerative colitis (UC) has on the lives of patients compared to other chronic conditions. Overall, 451 patients with UC, 309 with rheumatoid arthritis, 305 with asthma, and 305 with migraine headaches were recruited in an Internet survey designed to assess a variety of disease-impact indices.
RESULTS: Patients with UC reported a mean of eight (self-defined) flare-ups in the previous 12 months. Significantly more patients with UC (81%) believed that the quantity of flare-ups they experienced was 'normal', compared to patients with migraine headaches (64%) or asthma (75%). Patients with UC also reported significantly more worry about disease complications (84%), depression (62%), and embarrassment (70%) than patients with the other chronic conditions.
CONCLUSIONS: Compared to patients with other chronic conditions, patients with UC perceive substantially more negative impact upon their lives, especially with regard to the psychological burden.

Entities:  

Mesh:

Year:  2009        PMID: 20155319     DOI: 10.1007/s10620-009-0953-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  18 in total

Review 1.  Ulcerative colitis.

Authors:  S Ghosh; A Shand; A Ferguson
Journal:  BMJ       Date:  2000-04-22

2.  Cause of death in patients with inflammatory bowel disease.

Authors:  C Cucino; A Sonnenberg
Journal:  Inflamm Bowel Dis       Date:  2001-08       Impact factor: 5.325

3.  Guidelines for the management of inflammatory bowel disease in adults.

Authors:  M J Carter; A J Lobo; S P L Travis
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

4.  A practical perspective on ulcerative colitis: patients' needs from aminosalicylate therapies.

Authors:  Edward V Loftus
Journal:  Inflamm Bowel Dis       Date:  2006-12       Impact factor: 5.325

Review 5.  Inflammatory bowel disease: cause and immunobiology.

Authors:  Daniel C Baumgart; Simon R Carding
Journal:  Lancet       Date:  2007-05-12       Impact factor: 79.321

6.  Gender and disease activity influence health-related quality of life in inflammatory bowel diseases.

Authors:  Simone Saibeni; Ivan Cortinovis; Luigi Beretta; Maria Tatarella; Luca Ferraris; Emanuele Rondonotti; Ada Corbellini; Aurora Bortoli; Emilio Colombo; Costanza Alvisi; Gianni Imperiali; Roberto de Franchis
Journal:  Hepatogastroenterology       Date:  2005 Mar-Apr

7.  Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis.

Authors:  S V Kane; R D Cohen; J E Aikens; S B Hanauer
Journal:  Am J Gastroenterol       Date:  2001-10       Impact factor: 10.864

8.  Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis.

Authors:  Walter Reinisch; William J Sandborn; Mohan Bala; Songkai Yan; Brian G Feagan; Paul Rutgeerts; Graham Radford-Smith; Stephen Xu; Debra Eisenberg; Allan Olson; Jean Frédéric Colombel
Journal:  Inflamm Bowel Dis       Date:  2007-09       Impact factor: 5.325

9.  Colorectal cancer in ulcerative colitis. Influence of anatomical extent and age at onset on colitis-cancer interval.

Authors:  A Sugita; D B Sachar; C Bodian; M B Ribeiro; A H Aufses; A J Greenstein
Journal:  Gut       Date:  1991-02       Impact factor: 23.059

10.  Health-related quality of life in patients with inflammatory bowel disease five years after the initial diagnosis.

Authors:  T Bernklev; J Jahnsen; E Aadland; J Sauar; T Schulz; I Lygren; M Henriksen; N Stray; O Kjellevold; M Vatn; B Moum
Journal:  Scand J Gastroenterol       Date:  2004-04       Impact factor: 2.423

View more
  17 in total

1.  Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom.

Authors:  Michele R Wilson; Annika Bergman; Helene Chevrou-Severac; Ross Selby; Michael Smyth; Matthew C Kerrigan
Journal:  Eur J Health Econ       Date:  2017-03-08

2.  Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study.

Authors:  William J Sandborn; Jean-Frédéric Colombel; Subrata Ghosh; Bruce E Sands; Gerald Dryden; Xavier Hébuterne; Rupert W Leong; Brian Bressler; Thomas Ullman; Peter L Lakatos; Walter Reinisch; Li-An Xu; Allison Luo
Journal:  J Crohns Colitis       Date:  2015-12-30       Impact factor: 9.071

3.  Perceived Emotional and Psychological Impact of Ulcerative Colitis on Outpatients in Spain: UC-LIFE Survey.

Authors:  Antonio López-Sanromán; Daniel Carpio; Xavier Calvet; Cristina Romero; Luis Cea-Calvo; Berta Juliá; Federico Argüelles-Arias
Journal:  Dig Dis Sci       Date:  2016-11-05       Impact factor: 3.199

4.  Longitudinal results of cognitive behavioral treatment for youths with inflammatory bowel disease and depressive symptoms.

Authors:  Rachel D Thompson; Anna Craig; Emily A Crawford; Diane Fairclough; Joseph Gonzalez-Heydrich; Athos Bousvaros; Robert B Noll; David R DeMaso; Eva Szigethy
Journal:  J Clin Psychol Med Settings       Date:  2012-09

5.  Perception gaps between patients with ulcerative colitis and healthcare professionals: an online survey.

Authors:  Stefan Schreiber; Julián Panés; Edouard Louis; Derek Holley; Mandy Buch; Kristine Paridaens
Journal:  BMC Gastroenterol       Date:  2012-08-15       Impact factor: 3.067

Review 6.  Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials.

Authors:  Zong Mei Zhang; Wei Li; Xue Liang Jiang
Journal:  Gut Liver       Date:  2016-03       Impact factor: 4.519

Review 7.  Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis.

Authors:  Adrian D Vickers; Claire Ainsworth; Reema Mody; Annika Bergman; Caroline S Ling; Jasmina Medjedovic; Michael Smyth
Journal:  PLoS One       Date:  2016-10-24       Impact factor: 3.240

8.  Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK.

Authors:  Michele R Wilson; Ismail Azzabi Zouraq; Helene Chevrou-Severac; Ross Selby; Matthew C Kerrigan
Journal:  Clinicoecon Outcomes Res       Date:  2017-10-16

9.  Gastroenterologists' Perceptions Regarding Ulcerative Colitis and Its Management: Results from a Large-Scale Survey.

Authors:  Karen Lasch; Stephen Liu; Lyann Ursos; Reema Mody; Kristen King-Concialdi; Marco DiBonaventura; Julie Leberman; Marla Dubinsky
Journal:  Adv Ther       Date:  2016-08-10       Impact factor: 3.845

10.  Optimizing the multidimensional aspects of the patient-physician relationship in the management of inflammatory bowel disease.

Authors:  Deborah Chew; Wong Zhiqin; Norhayati Ibrahim; Raja Affendi Raja Ali
Journal:  Intest Res       Date:  2018-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.